Aspirin and the Prevention of Venous Thromboembolism

Becker, Richard C.
May 2012
New England Journal of Medicine;5/24/2012, Vol. 366 Issue 21, p2028
Academic Journal
The article discusses the effectiveness of aspirin in reducing the risk of venous thromboembolism. In 2002, a study found that an antiplatelet therapy led to a 39% reduction in the risk of venous thromboembolism in high-risk patients. It notes that the adverse-event profile of aspirin is acceptable to patients and physicians. Studies also found that patients who are at low-to-moderate risk for bleeding will benefit from an extended anticoagulant therapy.


Related Articles

  • Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic Review. Nascimento, Bruno Ramos; de Sousa, Marcos Roberto; Nogueira Demarqui, Fábio; Pinho Ribeiro, Antonio Luiz // ISRN Otolaryngology;2014, p1 

    Objectives. Assess the impact of associating thrombolytics, anticoagulants, antiplatelets, and primary angioplasty (PA) on death, reinfarction (AMI), and major bleeding (MB) in STEMI therapy. Methods. Medline search was performed to identify randomized trials comparing these classes in STEMI...

  • Electromyography in Anticoagulated Patients. Rubin, Michael // Neurology Alert;Mar2012, Vol. 30 Issue 7, p52 

    PATIENTS ON ANTIPLATELET AGENTS OR ANTICOAGULANTS OFTEN require needle electromyography (EMG), and the risk of hematoma formation and uncontrolled bleeding is often raised. Many EMG laboratories avoid studying such patients. No evidence-based guidelines exist, although it is generally...

  • Aspirin resistance: Where are we now? Abacı, Okay; Kılıçkesmez, Kadriye Orta // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Jun2013, Vol. 13 Issue 4, p370 

    Aspirin is an effective antiplatelet drug for preventing thrombo-embolic vascular events. However, clinical and laboratory evidence demonstrates diminished or no response to aspirin in some patients that is called aspirin resistance. This situation has been reported to be independently...

  • Long-term use of ticagrelor in patients with prior heart attack: ticagrelor plus aspirin versus aspirin monotherapy. Amico, Frank; Schlesinger, Alex; Mazzoni, Jennifer // Postgraduate Medicine;Mar2016, Vol. 128 Issue 2, p164 

    Review of: Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-1800. This Practice Pearl reviews the recent study Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor...

  • Antiplatelet and Anticoagulative Medication During Shockwave Lithotripsy. Schnabel, Marco J.; Gierth, Michael; Bründl, Johannes; Chaussy, Christian G.; Burger, Maximilian; Fritsche, Hans-Martin // Journal of Endourology;Sep2014, Vol. 28 Issue 9, p1034 

    Background and Purpose: Shockwave lithotripsy (SWL) is the gold standard treatment of patients with most renal and proximal ureteral calculi. Severe bleeding complications in SWL are extremely rare. Uncorrected bleeding diathesis might increase the risk and is considered to be an absolute...

  • High Maintenance Dosage of Clopidogrel is Associated with a Reduced Risk of Stent Thrombosis in Clopidogrel-Resistant Patients. Tavassoli, Neda; Voisin, Sophie; Carrie, Didier; Lapeyre-Mestre, Maryse; Galinier, Michel; Montastruc, Jean Louis; Pathak, Atul // American Journal of Cardiovascular Drugs;2010, Vol. 10 Issue 1, p29 

    Background: Stent thrombosis remains an important complication after stent implantation, despite the use of dual antiplatelet therapy with aspirin (acetylsalicylic acid) and clopidogrel. Several studies have shown an increased risk of thrombotic events in patients with resistance to clopidogrel....

  • The evolution of dual antiplatelet therapy in the setting of acute coronary syndrome: ticagrelor versus clopidogrel. Amico, Frank; Amico, Angela; Mazzoni, Jennifer; Moshiyakhov, Mark; Tamparo, William // Postgraduate Medicine;Mar2016, Vol. 128 Issue 2, p159 

    Review of: Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 2009; 361(11): 1045–1057. For acute coronary syndrome (ACS), a dual antiplatelet regimen comprised of treatment with aspirin and either P2Y12 adenosine...

  • Consistency is Key for Preventing Adverse Medication Effects.  // Women's Health Advisor;Mar2012, Vol. 16 Issue 3, p3 

    The article focuses on a study which investigates the effects of drugs to prevent blood clots and treat diabetes. The study found that four medications and medication classes such as warfarin, insulin, antiplatelet agents and oral hypoglycemic agents produce adverse serious effects that require...

  • From big data to bedside decision-making: the case for AdverseEvents. Biondi-Zoccai, Giuseppe; Cavarretta, Elena; Frati, Giacomo // Drugs & Therapy Studies;2013, Vol. 3 Issue 1, p13 

    Evidence-based medicine has gained mainstream popularity, but it requires a delicate balance between clinical evidence, physician skills, patient preferences, and costs. Facing the individual patient, even a simple decision such as which antithrombotic agent should be prescribed becomes complex....


Read the Article


Sign out of this library

Other Topics